Market Place
Sourcing Support
Aptose updates Tuspetinib-based triple drug therapy in AML trial
05 May 2025 //
GLOBENEWSWIRE
Faron Reports Positive Phase 2 Results in Myelodysplastic Syndrome
15 Apr 2025 //
ACCESSWIRE
Salarius Resumes Patient Enrollment in Seclidemstat Cancer Trial
03 Feb 2025 //
GLOBENEWSWIRE
Oryzon Doses First Patient In AML Trial With Iadademstat Combo
13 Jan 2025 //
GLOBENEWSWIRE
Hetero`s Generics Azacitidine Receives Approval in US
15 Oct 2024 //
FDA
ImCheck Receives FDA Fast Track For ICT01 In AML
18 Sep 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2024
08 Aug 2024 //
GLOBENEWSWIRE
First Patient Enrolled In US Phase 2 Trial Of Ligufalimab Combo
05 Aug 2024 //
PR NEWSWIRE
Shattuck Labs Reports Q2 2024 Results And Business Highlights
01 Aug 2024 //
GLOBENEWSWIRE
Immune-Onc Presents Positive IO-202 Data In CMML At EHA 2024
14 Jun 2024 //
BUSINESSWIRE
Shattuck Reports Positive SL-172154 Data In HR-MDS And TP53m AML
14 Jun 2024 //
GLOBENEWSWIRE
Shattuck Labs To Host Investor Call And Webcast On Additional Interim Data
06 Jun 2024 //
GLOBENEWSWIRE
Updated Lisaftoclax/Azacitidine AML Data Show Efficacy, Manageable Safety
04 Jun 2024 //
PR NEWSWIRE
HiberCell: First Patient Dosed In AML Combination Trial Of HC-7366
28 May 2024 //
GLOBENEWSWIRE
MSN Labs` Generic Azacitidine Receives Approval in the U.S.
16 May 2024 //
FDA
Shattuck Labs To Present SL-172154 + AZA Data In MDS/AML At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Salarius Reports Fourth Quarter and Full Year 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers
03 Jan 2024 //
GLOBENEWSWIRE
Akeso Published Results from CD47 Antibody Ligufalimab at ASH 2023
15 Dec 2023 //
PR NEWSWIRE
Shattuck Labs Announces Positive Data from Ongoing Phase 1 Trial of SL-172154
13 Dec 2023 //
GLOBENEWSWIRE
ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH
10 Dec 2023 //
BUSINESSWIRE
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117)
27 Sep 2023 //
PR NEWSWIRE
Gilead scraps late-stage trial of blood cancer treatment
22 Jul 2023 //
PRESS RELEASE
Intas Pharmaceuticals Limited on FDA Import Alert List
06 Jun 2023 //
FDA
Ph 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done
15 May 2023 //
BUSINESSWIRE
FDA puts Curis` leukemia trial on partial hold after patient death
04 Apr 2023 //
FIERCE BIOTECH
Eugia`s Generic Azacitidine Receives Approval in the U.S.
30 Dec 2022 //
FDA
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436
12 Dec 2022 //
ACCESSWIRE
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept
12 Dec 2022 //
GLOBENEWSWIRE
ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients
12 Dec 2022 //
GLOBENEWSWIRE
Innovent Presents Phase 1b Clinical Data of IBI188 at the 2022 ASH
10 Dec 2022 //
PRNEWSWIRE
ImmunoGen Presents Findings from Cohorts in Phase 1b/2 of Pivekimab Sunirine
10 Dec 2022 //
BUSINESSWIRE
TIBSOVO Available from Onco360 for the Treatment of IDH1-mutant AML
15 Sep 2022 //
BUSINESSWIRE
Servier leverages Mission Bio`s Tapestri Platform to uncover AML resistance
15 Sep 2022 //
APNEWS
I-Mab Announces Approval to Initiate PIII Study of Lemzoparlimab & Azacitidine
13 Sep 2022 //
PRNEWSWIRE
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab with Azacitidine
11 Sep 2022 //
PRNEWSWIRE
Enforcement Report - Week of August 24, 2022
24 Aug 2022 //
FDA
Enforcement Report - Week of August 17, 2022
17 Aug 2022 //
FDA
AbbVie calls off PI trial for I-Mab’s CD47 after Zai Lab shelves program
17 Aug 2022 //
ENDPTS
Syros Receives Positive Opinion on Orphan Drug Designation from the EMA
03 Aug 2022 //
BUSINESSWIRE
Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in AML
10 Jun 2022 //
GLOBENEWSWIRE
Servier expands Tibsovo label with first combination OK in a rare form of AML
27 May 2022 //
ENDPTS
Servier Announces FDA Approval of TIBSOVO in Combination with Azacitidine
26 May 2022 //
ASIAONE
BMS dusts off an old Celgene chemotherapy for use in children
23 May 2022 //
ENDPTS
Phase 3 AGILE Data of TIBSOVO® in Combination with Azacitidine
21 Apr 2022 //
PRNEWSWIRE
Enforcement Report - Week of March 02, 2022
02 Mar 2022 //
FDA
Amneal Expands Injectables Portfolio with 4 New Products
17 Feb 2022 //
BUSINESSWIRE
Amneal Pharmaceuticals` Generic Azacitidine Receives Approval in the U.S.
03 Feb 2022 //
FDA
Syros Receives FDA ODD for Tamibarotene for the Treatment of MDS
02 Feb 2022 //
BUSINESSWIRE
FDA orders Gilead to hit the brakes on their late-stage, $5B cancer play
26 Jan 2022 //
ENDPTS
Forma`s Olutasidenib+Azacitidine Yields Durable Complete Remission in mIDH1 AML
16 Dec 2021 //
BUSINESSWIRE
Astellas finds the silver lining in failed trial for Xospata
15 Dec 2021 //
FIERCEPHARMA
ALX Oncology Shows Initial Data from ASPEN-02, Phase 1 / 2 Study of Evorpacept
12 Dec 2021 //
PRESS RELEASE
ImmunoGen: Initial Findings From Phase 1b/2 Study of IMGN632+Vidaza & Venclexta
12 Dec 2021 //
BUSINESSWIRE
FDA Confirms Paragraph IV Patent Challenge of Azacitidine
17 Nov 2021 //
FDA
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza®
04 Nov 2021 //
BUSINESSWIRE
Aprea`s myeloid program iced by FDA on adverse events
07 Aug 2021 //
ENDPTS
Trillium Announces Dosing of 1st Patient in Ph1b/2 Study of TTI-622+Azacitidine
06 Jul 2021 //
GLOBENEWSWIRE
BMS Receives European Commission Approval for Onureg®
18 Jun 2021 //
BUSINESSWIRE
